NYXH
Nyxoah SAPrice
Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.
- R Mar 19 Nyxoah reported strong fourth-quarter and full-year 2025 financial r…
- A May 12 Stifel downgrades
- R Jun 8 Nyxoah priced a $95M gross underwritten public offering of 55.2M ord…
- R Jun 11 Nyxoah SA filed a 6-K on June 11, 2026, disclosing the issuance of 5…
- R Jun 23 Nyxoah disclosed receipt of $15M (€13.8M) from the second tranche of…
- X Aug 31 Short interest falls 48.5% to 244.3K
- R Oct 19 Nyxoah reported preliminary Q3 2026 global net revenue of €9.2M (19%…
- R Oct 20 Nyxoah reported preliminary Q3 2026 global net revenue of €9.2 milli…
Signal stack
Where each data set points today.
- InstitutionsMIXED
Q2 2026: 3 added (0 new), 1 trimmed or exited.
- AnalystsBULLISH
10 of 13 rate it Buy or better.
- EstimatesRISING
Current-quarter EPS estimate −$0.333 → −$0.320 over 90 days. 2 up, 1 down in 30 days.
- TrendDOWNTREND
39% below its 50-day average. New closing low $0.8220 on Oct 22.
Who's buying
13F· Q2 2026| Fund | Move | Value |
|---|---|---|
| BNP Paribas Asset Management Holding S.A. | ADD | $1.7M |
| BlackRock, Inc. | NEAR_EXIT | $204.8K |
| GEODE CAPITAL MANAGEMENT, LLC | DOUBLED | $75.7K |
| MORGAN STANLEY | ADD | $7.6K |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
13 analysts| Date | Firm | Rating |
|---|---|---|
| Aug 17, 2026 | Cantor Fitzgerald MAINTAIN | Overweight |
| Aug 6, 2026 | Piper Sandler REITERATE | Overweight |
| Jun 17, 2026 | Stifel MAINTAIN | Hold |
| May 13, 2026 | Piper Sandler REITERATE | Overweight |
| May 12, 2026 | Stifel DOWNGRADE | Hold |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | -$0.32 | -$0.54–-$0.21 | -0.8% | $9.9M |
| Next Q | -$0.15 | -$0.19–-$0.04 | +1.6% | $13.7M |
| Current FY | -$1.26 | -$1.40–-$1.17 | +0.0% | $35.4M |
| Next FY | -$0.73 | -$0.95–-$0.52 | +0.0% | $70.4M |
Short side
FINRA· Oct 15, 2026SecBot reports
10 filings · 3 press releases · 1 bullish · 7 bearish · 1 mixed · 1 neutral- BEARISH 6-KOct 20, 2026
Nyxoah reported preliminary Q3 2026 global net revenue of €9.2 million (up 19% sequentially) and…
The guidance cut signals slower-than-expected U.S. commercial ramp despite sequential growth. Watch for the FDA's decision on the PMA supplement for CCC indication, which could expand the…
- BEARISH PRESS-RELEASEOct 19, 2026
Nyxoah reported preliminary Q3 2026 global net revenue of €9.2M (19% sequential growth) and U.S…
The guidance cut signals slower-than-expected U.S. commercial ramp, which is the primary revenue growth driver. Watch for Q4 2026 actual revenue and the FDA's decision on the PMA supplement for CCC…
- NEUTRAL 6-KSep 22, 2026
Nyxoah announced CFO John Landry will step down effective October 2, 2026, with President…
Monitor the permanent CFO search and next quarterly update for any deviation from reaffirmed guidance. The interim CFO is a known insider with prior CFO experience, reducing transition risk.
- BEARISH 6-KJun 23, 2026
Nyxoah disclosed receipt of $15M (€13.8M) from the second tranche of its EIB loan facility…
The $15M EIB tranche provides non-dilutive cash, but the massive 126% dilution from the concurrent equity offering is the dominant event. Monitor the July 9 shareholder meeting: approval of…
All NYXH filing & press-release reports (13)
- 6-K reportOct 20, 2026
- PRESS-RELEASE reportOct 19, 2026
- 6-K reportSep 22, 2026
- 6-K reportJun 23, 2026
- 6-K reportJun 11, 2026
- 6-K reportJun 8, 2026
- 424B5 reportJun 8, 2026
- PRESS-RELEASE reportJun 5, 2026
- 424B5 reportJun 4, 2026
- PRESS-RELEASE reportMay 20, 2026
- PRESS-RELEASE reportMay 12, 2026
- PRESS-RELEASE reportMar 19, 2026
- PRESS-RELEASE reportMar 5, 2026